Antiangiogenic Therapies: Going beyond Their Limits

摘要: Tumor growth requires induction of an angiogenic program, and targeting this program with antiangiogenic drugs shows impact on tumor progression. However, although they are effective at reducing angiogenesis, these therapies have not produced widespread or enduring clinical benefit, which openly exposes their limitations. Here, we describe the current limitations therapies, including known mechanisms controversies. Further, present some recent approaches to predict strategies overcome them. With development meaningful predictive biomarkers treatments that impede limitations, longer more robust efficacies will be achieved for a wider population patients.